CompanyAmyris, Inc.
United States of America
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its no compromise products and services across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nut...
Private/Public:
public
Phone:(510) 450-0761
Fax:(510) 225-2645
Email:[email protected]
Website:https://amyris.com/
Address:5885 Hollis Street, Suite 100 Emeryville, CA 94608, United States of America
Business Sectors
For Services/Products
API/Biologicals Production
API/Biologics development and manufacturing
Reagents/excipients manufactured
| Facility Type | Address | Telephone | City | Fax | Country | State Code | Service Categories | Facility Size | Year Built | Number Of Employees | Note |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Regional/Country Headquarters | Rua John Dalton, 301 - Bloco B - Edificio 3 Condominio Techno Plaza Campinas, SP 13069-330 | +55 (19) 3783-9450 | Campinas | +55 (19) 3341-9360 | Brazil | ||||||
| Regional/Country Headquarters | Av. Roque Petroni Jr. 850, 16 ° andar, Torre Bacaetava, São Paulo, SP 04707-000 | +55-11-3230-1710 | Brazil | ||||||||
| Global Corporate Headquarters | 5885 Hollis Street, Suite 100 Emeryville, CA 94608 | (510) 450-0761 | Emeryville | (510) 225-2645 | United States of America | CA-California |
- (02.Mar.2021) Amyris, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results
- (01.Mar.2021) Amyris Acquiring Costa Brazil Clean Beauty Brand - Francisco Costa to Join Amyris as Chief Creative Officer
- (24.Feb.2021) Amyris Announces Launch of Pipette Clean Baby Care Brand in Target Retail Stores Across North America
- (23.Feb.2021) Amyris and The Infectious Disease Research Institute Enter into Exclusive License for Novel RNA Vaccine Platform, Beginning with COVID-19 Vaccine
- (22.Feb.2021) Amyris Announces Positive Pre-Clinical Results for COVID-19 RNA Vaccine Platform With Advantaged Manufacturing, Storage and Distribution Characteristics
- (02.Feb.2021) Amyris Announces Breakthrough Clinical Results for Its Clean Formulation Acne Treatment
- (22.Jan.2021) Amyris Acquiring Terasana Brand to Offer Clean Cannabinoid Consumer Products
- (21.Dec.2020) Amyris Closes $50 Million Strategic Transaction
- (16.Dec.2020) Amyris Hosts Successful First Session of Its Virtual Investor Mini-Series
- (30.Nov.2020) Amyris Delivers Record Black Friday Sales
- (05.Nov.2020) Amyris, Inc. Reports Third Quarter 2020 Financial Results
- (20.Oct.2020) Amyris and Arzeda Enter into Development Collaboration Agreement
- (01.Oct.2020) Amyris Delivering Sustainable Alternative to Shark Squalene Adjuvant - Enabling Vaccines for All With No Sharks Killed
- (11.Sep.2020) Amyris Responds to LAVVAN's Filing of Lawsuit on September 10, 2020
- (10.Sep.2020) LAVVAN, Inc. Files $881 Million Federal Lawsuit Against Amyris, Inc. For Patent Infringement and Trade Secret Misappropriation
- (06.Aug.2020) Amyris, Inc. Reports Second Quarter 2020 Results
- (27.Jul.2020) Amyris and the Infectious Disease Research Institute Partner to Advance Novel RNA Vaccine Platform Beginning With COVID-19 Application
- (15.Jul.2020) Amyris Launches Plant-Derived Sustainable Silica for Clean Beauty Applications
- (30.Jun.2020) Biossance Announces Clean Academy Impact Award and Partnership With Oceana
- (10.Jun.2020) Amyris Announces Closing of $200 Million Private Placement
- (04.Jun.2020) Amyris Raises $200 Million From Private Placement
- (15.May.2020) Amyris Changes Its 2020 Annual Meeting of Stockholders to Virtual Format
- (14.May.2020) Amyris Receives GRAS Validation by Medical Expert Panel for Its New Health and Nutrition Ingredient
- (08.May.2020) Amyris, Inc. Reports First Quarter 2020 Results
- (26.Mar.2020) Amyris Launches Leading Hand Sanitizer and Receives Initial Positive Result for Vaccine Adjuvant
- (19.Mar.2020) Amyris Provides Business Update
- (12.Mar.2020) Amyris Reports Another Strong Quarter of Recurring Revenue Growth